| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Crizotinib | gCSI | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | Doxorubicin | CTRPv2 | pan-cancer | AAC | 0.03 | 0.3 |
| mRNA | BRD-K24690302 | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | CAY10594 | CTRPv2 | pan-cancer | AAC | 0.037 | 0.3 |
| mRNA | LY-2183240 | CTRPv2 | pan-cancer | AAC | 0.031 | 0.3 |
| mRNA | BMS-754807 | CTRPv2 | pan-cancer | AAC | 0.034 | 0.3 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | 0.033 | 0.3 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.044 | 0.3 |
| mRNA | BRD-A05715709 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.3 |